Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

Dana-Farber Cancer Institute

Status and phase

Completed

Phase 2

Conditions

Chronic Graft Versus Host Disease

Treatments

Drug: Prednisone

Drug: bortezomib

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00815919

08-191

Details and patient eligibility

About

The purpose of this research study is to determine the effectiveness of bortezomib (Velcade) plus prednisone for treating chronic graft versus host disease (cGVHD) and the safety of this drug combination in this patient population. Chronic GVHD is a medical condition that may occur after allogeneic stem cell transplantation. The donor's immune system may recognize the participants body (the host) as foreign and attempt to "reject" it. Bortezomib has been used in other research studies, and information from those studies suggests that this drug may help to control the abnormal immune responses that underlie cGVHD.

Full description

Each treatment cycle lasts five weeks, during which time participants will come to the clinic to receive bortezomib intravenously once a week for the first 4 weeks. Prednisone will be taken orally on a daily basis and dose reduction may be initiated after 1 cycle of therapy.
During all treatment cycles, participants will have the following: physical exam and blood work. At the end of cycle 3 (week 15) the participants cGVHD will be evaluated. These assessments may include an eye examination, a skin examination, a pulmonary function test and/or, a flexion assessment test.
Participants will receive 3 cycles of bortezomib.

Enrollment

22 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Recipients of allogeneic stem cell transplantation with myeloablative or non-myeloablative conditioning regimens
100 days or more past stem cell transplantation
Recipients of matched or mismatched, related or unrelated adult donor stem cells
Must have cGVHD requiring systemic therapy
No addition or subtraction of other immunosuppressive medications. The dose of immunosuppressive medicines may be adjusted based on the therapeutic range of that drug. However, if cGVHD occurs during a taper of immune suppression, the medication(s) may not be increased back up to therapeutic level, but will continue a the taper dose for the 15 week study duration
Adequate bone marrow, hepatic and renal function as outlined in the protocol
Does not require hemodialysis
18 years of age or older
ECOG Performance Status of 0-2 or Karnofsky performance score of 70% or greater
Life expectancy of more than 3 months

Exclusion criteria

Systemic steroid therapy in the 4 weeks prior to enrollment
Active malignant disease after transplantation. Complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy will not be considered in this category
Active uncontrolled infection
Peripheral neuropathy CTC Grade 1 (or greater) with pain in the 4 weeks before enrollment. Other neurological deficits must be reviewed with the study PI prior to study entry
Myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
Hypersensitivity to bortezomib, boron, or mannitol
Female subject is pregnant or breast-feeding
Serious medical or psychiatric illness likely to interfere with participation in this clinical study